# Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes

> **NCT05205005** · PHASE2,PHASE3 · COMPLETED · sponsor: **VA Office of Research and Development** · enrollment: 24 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Endocalyx
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05205005
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-25
- **Primary completion:** 2024-03-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05205005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05205005, "Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT05205005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*